GRANULES INDIA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 418.1 INR | +0.87% |
|
+0.57% | +3.12% |
| Apr. 15 | Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit | MT |
| Apr. 03 | Granules India Unit Gets VAI Status for Virginia Facility | MT |
| Sales 2024 * | 45.62B 548M | Sales 2025 * | 52.56B 631M | Capitalization | 101B 1.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.18B 50.23M | Net income 2025 * | 6.04B 72.52M | EV / Sales 2024 * | 2.4 x |
| Net Debt 2024 * | 8.13B 97.55M | Net Debt 2025 * | 8.32B 99.89M | EV / Sales 2025 * | 2.08 x |
| P/E ratio 2024 * |
24.5
x | P/E ratio 2025 * |
16.9
x | Employees | 3,650 |
| Yield 2024 * |
0.33% | Yield 2025 * |
0.33% | Free-Float | 53.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Granules India Limited
More press releases
| 1 day | +0.87% | ||
| 1 week | +0.57% | ||
| Current month | -2.80% | ||
| 1 month | -2.94% | ||
| 3 months | +1.51% | ||
| 6 months | +25.71% | ||
| Current year | +3.12% |
1 week
404.40
424.45
1 month
404.40456.45
Current year
400.00480.45
1 year
272.35480.45
3 years
226.95480.45
5 years
84.00480.45
10 years
31.12480.45
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 60 | 22-01-04 | |
| Chief Executive Officer | 69 | 91-03-17 | |
Mukesh Surana
DFI | Director of Finance/CFO | 44 | 22-12-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 13-02-18 | |
| Director/Board Member | 62 | 21-12-12 | |
| Director/Board Member | 67 | Feb. 19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 418.1 | +0.87% | 568,508 |
| 24-04-23 | 414.5 | +0.04% | 294,332 |
| 24-04-22 | 414.4 | +0.73% | 435,404 |
| 24-04-19 | 411.4 | -0.80% | 588,576 |
| 24-04-18 | 414.6 | -0.26% | 732,357 |
Delayed Quote NSE India S.E., April 24, 2024 at 07:40 am EDT
More quotes
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
417.8
INR
Average target price
483.4
INR
Spread / Average Target
+15.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- GRANULES Stock
- GRANULES Stock
